| Shaughnessy, Paul |
FELIX, NCT04404660: A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) |
|
|
| Active, not recruiting | 1/2 | 153 | Europe, US | AUTO1, Obecabtagene autoleucel (obe-cel) | Autolus Limited | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | 05/25 | 05/25 | | |
CARBON, NCT04035434: A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies |
|
|
| Active, not recruiting | 1/2 | 227 | Europe, Canada, US, RoW | CTX110 | CRISPR Therapeutics AG | B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL | 07/26 | 08/26 | | |
| Recruiting | 1/2 | 225 | Europe, Japan, US, RoW | Rapcabtagene autoleucel single agent, Ibrutinib | Novartis Pharmaceuticals | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | 06/27 | 06/27 | | |
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients |
|
|
| Available | N/A | | Canada, US, RoW | CTL019, tisagenlecleucel, Kymriah | Novartis Pharmaceuticals | Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL) | | | | |
| Kandzari, David E |
| Active, not recruiting | 3 | 300 | US | Dehydrated alcohol, Ethanol, Peregrine System Kit (Sham Procedure) | Ablative Solutions, Inc. | Hypertension | 12/23 | 05/26 | | |
| Completed | N/A | 366 | Europe, Canada, Japan, US, RoW | Symplicity Spyral™ multi-electrode renal denervation system, Renal angiography, Renal Denervation, Sham Procedure | Medtronic Vascular | Hypertension, Vascular Diseases, Cardiovascular Diseases | 04/20 | 10/23 | | |
| Active, not recruiting | N/A | 750 | US | | Saint Luke's Health System, Piedmont Heart Institute, Inc., Atlanta, GA | Coronary Artery Disease | 06/20 | 06/25 | | |
BIOFLOW-VII, NCT04175626: Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions |
|
|
| Active, not recruiting | N/A | 556 | US | Orsiro DES, Orsiro sirolimus coronary stent system | Biotronik, Inc. | Coronary Artery Disease, Atherosclerosis, Coronary, Myocardial Ischemia, Ischemic Heart Disease, Acute Coronary Syndrome, Angina Pectoris | 01/22 | 01/26 | | |
NCT02439775: SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System |
|
|
| Active, not recruiting | N/A | 337 | Europe, Canada, Japan, US, RoW | Symplicity Spyral™ multi-electrode renal denervation system, Renal angiography, Renal Denervation, Sham Procedure | Medtronic Vascular | Hypertension, Vascular Diseases, Cardiovascular Diseases | 08/22 | 10/25 | | |
CRYSTAL, NCT03423511: Trial to Demonstrate the Safety and Effectiveness of the MiStent II for the Revascularization of Coronary Arteries. |
|
|
| Not yet recruiting | N/A | 1300 | NA | MiStent II coronary artery stent, Xience or Promus coronary artery stents | Micell Technologies, Baim Institute for Clinical Research, North American Science Associates Inc., Yale Cardiovascular Research Group | Coronary Artery Disease | 06/23 | 06/27 | | |
NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN |
|
|
| Recruiting | N/A | 1400 | Europe, US, RoW | Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation | Medtronic Vascular | Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus | 11/26 | 11/29 | | |
NCT04849169: Investigation of the Ringer Perfusion Balloon Catheter |
|
|
| Completed | N/A | 30 | US | Experimental | Vascular Solutions LLC | Coronary Artery Perforation | 11/23 | 11/23 | | |
| Not yet recruiting | N/A | 170 | NA | Sapphire 3 Coronary Dilatation Catheter | OrbusNeich, Avania | Coronary Artery Disease, Coronary Disease, Myocardial Ischemia, Heart Diseases, Arteriosclerosis, Cardiovascular Diseases, Chronic Total Occlusion, Chronic Total Occlusion of Coronary Artery | 07/25 | 07/25 | | |
| Recruiting | N/A | 500 | Europe, US, RoW | Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated, BackBeat CNT, Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated | Orchestra BioMed, Inc, Medtronic | Hypertension, Hypertension, Systolic, Hypertension,Essential | 10/25 | 06/28 | | |
| Contact, Use Central |
| Recruiting | 4 | 30 | US | IgPro10, Privigen | CSL Behring | Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | 12/29 | 12/29 | | |
NCT04167514: Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705) |
|
|
| Active, not recruiting | 3 | 136 | US | Alpha-1 antitrypsin (AAT), Alpha-1 proteinase inhibitor (A1-P1), Placebo | CSL Behring, Blood and Marrow Transplant Clinical Trials Network, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI) | Graft Versus Host Disease (GVHD) | 05/24 | 05/24 | | |
| Active, not recruiting | 3 | 126 | Europe, Japan, US, RoW | human immunoglobulin G, IgPro20, Hizentra, Placebo | CSL Behring, CSL Behring LLC, 1020 First Avenue, King of Prussia, PA 19406 | Dermatomyositis | 05/28 | 05/28 | | |
NCT05819775: CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema |
|
|
| Recruiting | 3 | 20 | Europe, Canada, US, RoW | CSL312, Garadacimab | CSL Behring | Hereditary Angioedema (HAE) | 11/26 | 11/26 | | |
| Terminated | 3 | 194 | Europe, Canada, US, RoW | Clazakizumab, Physiologic saline solution | CSL Behring, ICON Clinical Research | Antibody-mediated Rejection | 04/24 | 04/24 | | |
NCT06003387: Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs) |
|
|
| Recruiting | 3 | 35 | Canada, US, RoW | CSL222 (AAV5-hFIXco-Padua), Etranacogene dezaparvovec | CSL Behring | Hemophilia B | 10/28 | 10/28 | | |
MODULAATE, NCT03805789: The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant |
|
|
| Recruiting | 2/3 | 310 | Europe, Japan, US, RoW | Alpha-1 antitrypsin (AAT), Alpha-1 proteinase inhibitor, Placebo | CSL Behring | Acute-graft-versus-host Disease | 09/25 | 03/27 | | |
NCT05485961: Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis |
|
|
| Enrolling by invitation | 2/3 | 2310 | Europe, Canada, US, RoW | CSL300, Clazakizumab, Placebo | CSL Behring | Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease | 12/28 | 12/28 | | |
NCT01294020 / 2010-020925-42: Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf® |
|
|
| Active, not recruiting | 2 | 81 | Europe, RoW | Tacrolimus, Prograf, FK506, Tacrolimus prolonged release, FK506E, MR4, Advagraf, tacrolimus modified release, Astagraf XL, Graceptor, Prograf XL | Astellas Pharma Europe Ltd. | Intestine Transplantation, Kidney Transplantation, Lung Transplantation, Liver Transplantation, Heart Transplantation | 10/15 | 05/26 | | |
STARBORN-1, NCT05871970: Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age |
|
|
| Recruiting | 2 | 38 | US | TARA-002 | Protara Therapeutics | Lymphatic Malformation | 12/25 | 05/26 | | |
ADVANCED-2, NCT05951179: Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer |
|
|
| Recruiting | 2 | 127 | US, RoW | TARA-002 | Protara Therapeutics | Non-muscle Invasive Bladder Cancer | 05/30 | 08/30 | | |
NCT04446000: Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects |
|
|
| Terminated | 1 | 52 | Europe | CSL730, Recombinant trivalent human IgG1 Fc multimer, Placebo | CSL Behring | Immune Complex-mediated Autoimmune Diseases | 03/23 | 03/23 | | |
NCT05653713: Effects of CSL324 in the Lung After Segmental Challenge |
|
|
| Completed | 1 | 40 | Europe | CSL324, Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody (mAb), Placebo | CSL Behring | Healthy Volunteers | 07/23 | 07/23 | | |
NCT04082754: A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers |
|
|
| Completed | 1 | 78 | Europe | Human beta common receptor antagonist monoclonal antibody, CSL311, Placebo | CSL Behring | Asthma | 11/23 | 11/23 | | |
ADVANCED-1, NCT05085990: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer |
|
|
| Recruiting | 1 | 12 | US | TARA-002 | Protara Therapeutics | Non-muscle Invasive Bladder Cancer | 06/24 | 08/24 | | |
ADVANCED-1, NCT05085977: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) |
|
|
| Recruiting | 1 | 18 | Europe, US, RoW | TARA-002 | Protara Therapeutics | Non-muscle Invasive Bladder Cancer | 06/24 | 07/24 | | |
NCT05937581: First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects |
|
|
| Recruiting | 1 | 60 | RoW | CSL040, Placebo | CSL Behring | Complement Deficiencies | 03/25 | 03/25 | | |
| Completed | N/A | 80 | Europe, US | | Protara Therapeutics | Intestinal Failure-associated Liver Disease | 06/23 | 06/23 | | |
IX-TEND 4001, NCT06008938: An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B |
|
|
| Recruiting | N/A | 500 | US | HEMGENIX, Etranacogene dezaparvovec, Factor IX (FIX) | CSL Behring | Hemophilia B | 08/43 | 08/43 | | |
| Patel, Amar |
NCT03816254: A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, With Cetuximab in Subjects With Advanced Solid Cancers |
|
|
| Not yet recruiting | 1 | 140 | NA | CC-95251, Cetuximab | Celgene | Neoplasms | 04/22 | 11/23 | | |
NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN |
|
|
| Recruiting | N/A | 1400 | Europe, US, RoW | Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation | Medtronic Vascular | Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus | 11/26 | 11/29 | | |
| Recruiting | N/A | 500 | US | VIA Disc NP | VIVEX Biologics, Inc., Moxie Clinical | Discogenic Pain, Back Pain, Back Pain, Low | 01/27 | 01/27 | | |
| Recruiting | N/A | 750 | Europe, Canada, US, RoW | Corvia Atrial Shunt System / IASD System II, Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) | Corvia Medical | Heart Failure, Heart Failure, Diastolic | 05/25 | 03/31 | | |
SUMMIT, NCT03433274: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation |
|
|
| Recruiting | N/A | 958 | Canada, US | Tendyne Mitral Valve System, MitraClip System | Abbott Medical Devices | Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease | 06/24 | 06/28 | | |
| Nathan, Sandeep |
NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN |
|
|
| Recruiting | N/A | 1400 | Europe, US, RoW | Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation | Medtronic Vascular | Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus | 11/26 | 11/29 | | |
| Recruiting | N/A | 5000 | US | Vasopressor, Inotrope, Acute Mechanical Circulatory Support Devices | Tufts Medical Center, Abbott, Boston Scientific Corporation, Abiomed Inc., Getinge Group | Cardiogenic Shock | 01/25 | 06/25 | | |
| Xu, Wei |
ICP-CL-01203, NCT06378138: ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
| Not yet recruiting | 2/3 | 226 | RoW | ICP-248, Orelabrutinib | Beijing InnoCare Pharma Tech Co., Ltd. | Hematologic Malignancies | 11/30 | 07/31 | | |
| Completed | 2 | 3 | RoW | ICP-022 | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma | 11/21 | 12/21 | | |
NCT05716087: A Study of LP-168 in Participants With Relapse or Refractory Mantle Cell Lymphoma |
|
|
| Recruiting | 2 | 62 | RoW | LP-168, NWP-775 | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma (MCL) | 02/24 | 12/25 | | |
NCT04808570: A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
| Terminated | 1/2 | 23 | RoW | TQ-B3525 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 11/23 | 11/23 | | |
TEACH, NCT04281420: A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma |
|
|
| Terminated | 1 | 20 | RoW | ATG-019, KPT-9274, ATG-019 + Niacin ER | Antengene Therapeutics Limited | Solid Tumor, Non-Hodgkin's Lymphoma | 10/23 | 10/23 | | |
NCT05683717: A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies |
|
|
| Recruiting | 1 | 37 | RoW | TT-01488 Tablets | TransThera Sciences (Nanjing), Inc. | B-Cell Malignancies | 10/26 | 10/28 | | |
NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN |
|
|
| Recruiting | N/A | 1400 | Europe, US, RoW | Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation | Medtronic Vascular | Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus | 11/26 | 11/29 | | |
| Not yet recruiting | N/A | 768 | RoW | early pancreatic stent placement (EPSP), late pancreatic stent placement (EPSP) | The First Affiliated Hospital of Anhui Medical University, First Affiliated Hospital Bengbu Medical College, Anqing Municipal Hospital, First Affiliated Hospital of Wannan Medical College, Tongcheng People's Hospital of Anhui province, Fuyang people's hospital | Cholangiopancreatography, Endoscopic Rretrograde, Post-ERCP Pancreatitis | 03/26 | 03/26 | | |
| Recruiting | N/A | 380 | Canada, US | Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry | Neovasc Inc., Shockwave Medical, Inc. | Refractory Angina | 06/24 | 12/28 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 01/25 | 01/25 | | |
NCT05677100: Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure |
|
|
| Recruiting | N/A | 268 | US | Aortix System, Aortix Pump | Procyrion | Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome, ADHF, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure; With Decompensation, Heart Failure, Congestive | 07/25 | 12/25 | | |
| Brown, John |
| Recruiting | N/A | 1247 | Europe, Canada, US | Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System | Edwards Lifesciences | Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation | 01/25 | 04/30 | | |
| Recruiting | N/A | 160 | US | InSpace Subacromial Tissue Spacer | Stryker Endoscopy | Rotator Cuff Tears | 04/24 | 04/25 | | |
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. |
|
|
| Recruiting | N/A | 1056 | Europe, Canada, US | Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) | Medtronic Cardiovascular | Mitral Valve Regurgitation | 10/26 | 09/36 | | |
| Pederson, David |
| Recruiting | N/A | 1000 | US | WATCHMAN FLX Pro LAAC Device, Left Atrial Appendage Closure | Boston Scientific Corporation | Atrial Fibrillation, Bleeding, Stroke | 08/24 | 06/25 | | |
| Recruiting | N/A | 200 | US | electrophysiology study and ablation with an Abbott Ablation Catheter | Abbott Medical Devices | Atrial Arrhythmia, Atrium; Fibrillation, Atrial Tachycardia | 10/24 | 11/26 | | |
NCT04431544: AcQMap® US Registry of Procedural and Long-term Clinical Outcomes (Discover-US) |
|
|
| Terminated | N/A | 513 | US | AcQMap System | Acutus Medical | Ablation of Arrhythmia's | 11/23 | 11/23 | | |
| Kunavarapu, Chandra |
| Completed | N/A | 550 | Europe, US | Catheter-Directed Thrombolysis, FlowTriever System | Inari Medical | Pulmonary Embolism, Pulmonary Thrombo-embolism | 03/24 | 04/24 | | |
| Recruiting | N/A | 1200 | Europe, Canada, US | FlowTriever System, Anticoagulation Agents | Inari Medical | Pulmonary Embolism | 07/26 | 07/26 | | |
NCT05934487: PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III |
|
|
| Recruiting | N/A | 1650 | US | Cordella™ Pulmonary Artery Sensor System | Endotronix, Inc. | Heart Failure NYHA Class II, Heart Failure NYHA Class III | 09/27 | 09/29 | | |
| Mayoral, Jaime |
| Active, not recruiting | N/A | 44467 | US | | Guardant Health, Inc., Premier Research Group plc | Colorectal Cancer | 03/24 | 12/25 | | |
| Devireddy, Chandan |
| Recruiting | N/A | 1150 | US, RoW | Portico transcatheter aortic valve, Commercially available transcatheter aortic valve | Abbott Medical Devices | Aortic Valve Stenosis | 10/19 | 07/25 | | |
NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN |
|
|
| Recruiting | N/A | 1400 | Europe, US, RoW | Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation | Medtronic Vascular | Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus | 11/26 | 11/29 | | |
NCT05677100: Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure |
|
|
| Recruiting | N/A | 268 | US | Aortix System, Aortix Pump | Procyrion | Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome, ADHF, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure; With Decompensation, Heart Failure, Congestive | 07/25 | 12/25 | | |
| Cruz, Jose De La |
| Active, not recruiting | 3 | 245 | Europe, Canada, Japan, US, RoW | Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone | Takeda | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | 08/22 | 07/27 | | |
|
|
| Recruiting | 2/3 | 1912 | Canada, US | Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month | NRG Oncology, Natera, Inc., National Cancer Institute (NCI) | Stage III Colon Cancer | 03/29 | 03/30 | | |
| Perez, Jose |
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease |
|
|
| Active, not recruiting | 3 | 17006 | Europe, Canada, Japan, US, RoW | Inclisiran sodium 300 mg, Placebo | Novartis Pharmaceuticals | Atherosclerotic Cardiovascular Disease | 10/27 | 10/27 | | |
| Recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma | 02/25 | 08/28 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
| Active, not recruiting | 1/2 | 429 | Europe, US, RoW | Acasunlimab, GEN1046, DuoBody®-PD-L1x4-1BB, Acasunlimab in combination with docetaxel (in a single expansion cohort), Acasunlimab in combination with pembrolizumab (in a separate expansion cohort), Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts) | Genmab, BioNTech SE | Solid Tumors, Non-small Cell Lung Cancer, Urothelial Carcinoma, Endometrial Carcinoma, Triple Negative Breast Cancer, Squamous Cell Carcinoma of the Head and Neck, Cervical Cancer | 01/25 | 10/25 | | |
| McCracken, JoDell |
RCT, NCT05113927: Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery. |
|
|
| Recruiting | N/A | 531 | US | Selene | Perimeter Medical Imaging, Cancer Prevention Research Institute of Texas, Proxima Clinical Research, Biostatistical Consulting, Inc. | Breast Cancer | 10/24 | 01/25 | | |
| Ono, Masahiro |
| Active, not recruiting | N/A | 1017 | US | Impella 5.5 | Abiomed Inc. | Cardiogenic Shock, Acute Decompensated Heart Failure | 12/24 | 12/24 | | |
| Active, not recruiting | N/A | 350 | US | OCS Heart System | TransMedics | Transplant | 12/25 | 12/29 | | |
| Rutkin, Bruce |
| Active, not recruiting | N/A | 572 | Europe, Canada, US | TriClipTM Device | Abbott Medical Devices | Tricuspid Regurgitation | 11/22 | 04/29 | | |
| Recruiting | N/A | 1247 | Europe, Canada, US | Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System | Edwards Lifesciences | Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation | 01/25 | 04/30 | | |
| Recruiting | N/A | 1070 | Europe, US | Edwards EVOQUE System, Transcatheter tricuspid valve replacement, Optimal Medical Therapy | Edwards Lifesciences | Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure | 06/24 | 12/29 | | |
| Recruiting | N/A | 870 | Canada, US | Edwards PASCAL System, Transcatheter tricuspid valve repair (TTVr), Optimal Medical Therapy | Edwards Lifesciences | Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease | 12/24 | 03/29 | | |
| Recruiting | N/A | 650 | Europe, Canada, Japan, US, RoW | Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT) | Medtronic Cardiovascular | Moderate Aortic Valve Stenosis | 02/26 | 12/34 | | |
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. |
|
|
| Recruiting | N/A | 1056 | Europe, Canada, US | Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) | Medtronic Cardiovascular | Mitral Valve Regurgitation | 10/26 | 09/36 | | |
| Alvarez, Jorge |
| Recruiting | N/A | 501 | RoW | HIV-1 plasma RNA Genotyping secuencing by Sanger technique, Sanger Sequencing, HIV-1 plasma RNA Genotyping secuencing by Ultra-deep sequencing technique, Next-Generation Sequencing | Fundacion REVIVA, Red de VIH del Valle del Cauca, ViiV Healthcare, Centro de Investigación en. Enfermedades Infecciosas, Mexico | HIV Infection | 07/23 | 09/23 | | |
NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN |
|
|
| Recruiting | N/A | 1400 | Europe, US, RoW | Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation | Medtronic Vascular | Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus | 11/26 | 11/29 | | |
NCT03735667: ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement |
|
|
| Recruiting | N/A | 2820 | Canada, US | ACURATE neo2™ Transfemoral TAVR System, Medtronic CoreValve TAVR System, Edwards SAPIEN 3 TAVR System, ACURATE Prime™ Transfemoral TAVR System XL | Boston Scientific Corporation | Aortic Stenosis | 06/24 | 11/34 | | |
CorCinch-HF, NCT04331769: Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study |
|
|
| Recruiting | N/A | 400 | Europe, US, RoW | AccuCinch Ventricular Restoration System, Guideline-Directed Medical Therapy | Ancora Heart, Inc. | Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy | 06/24 | 12/30 | | |
| Recruiting | N/A | 650 | Europe, Canada, Japan, US, RoW | Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT) | Medtronic Cardiovascular | Moderate Aortic Valve Stenosis | 02/26 | 12/34 | | |
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. |
|
|
| Recruiting | N/A | 1056 | Europe, Canada, US | Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) | Medtronic Cardiovascular | Mitral Valve Regurgitation | 10/26 | 09/36 | | |
REDUCE PAS, NCT03821129: GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study |
|
|
| Recruiting | N/A | 636 | US | PFO closure with GORE® CARDIOFORM Septal Occluder | W.L.Gore & Associates | Stroke, PFO - Patent Foramen Ovale | 12/26 | 12/29 | | |
| Genereux, Philippe |
NCT02661451: Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD) |
|
|
| Active, not recruiting | N/A | 178 | Europe, Canada, US | SAPIEN 3 THV, Optimal Heart Failure Therapy | Cardiovascular Research Foundation, New York, Cardialysis BV, Avania | Aortic Valve Stenosis | 02/23 | 02/25 | | |
| Recruiting | N/A | 1247 | Europe, Canada, US | Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System | Edwards Lifesciences | Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation | 01/25 | 04/30 | | |
| Not yet recruiting | N/A | 50 | US | Shortcut | Pi-cardia | Valve-in-valve Procedures, Aortic Stenosis, Coronary; Obstruction | 04/25 | 09/25 | | |
CorCinch-HF, NCT04331769: Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study |
|
|
| Recruiting | N/A | 400 | Europe, US, RoW | AccuCinch Ventricular Restoration System, Guideline-Directed Medical Therapy | Ancora Heart, Inc. | Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy | 06/24 | 12/30 | | |
NCT03523416: Early Feasibility Study - Transcatheter Atrial Shunt System |
|
|
| Recruiting | N/A | 75 | US | Transcatheter Atrial Shunt System | Edwards Lifesciences | Heart Failure | 12/24 | 12/26 | | |
| Recruiting | N/A | 15 | US | AltaValve | 4C Medical Technologies, Inc. | Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Incompetence, Mitral Valve Regurgitation, Mitral Incompetence | 09/25 | 09/25 | | |
| Recruiting | N/A | 500 | Europe, Canada, US | MitraClip™ device implantation, Mitral Valve Repair Surgery | Abbott Medical Devices | Mitral Valve Regurgitation | 04/26 | 04/34 | | |
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. |
|
|
| Recruiting | N/A | 1056 | Europe, Canada, US | Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) | Medtronic Cardiovascular | Mitral Valve Regurgitation | 10/26 | 09/36 | | |
| Contact, Site Public |
| Completed | 4 | 50 | RoW | ADVATE | Baxalta now part of Shire, Takeda Development Center Americas, Inc. | Hemophilia A | 02/23 | 02/23 | | |
SWITCH, NCT04718779: A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy |
|
|
| Completed | 4 | 4 | US | Digital Engagement Application (GD App), No Intervention | Takeda | Gaucher Disease | 02/23 | 02/23 | | |
| Active, not recruiting | 4 | 200 | US | CDPATH™, PROSPECT, Blood Draw | Takeda | Crohn's Disease | 08/23 | 06/26 | | |
| Recruiting | 4 | 80 | RoW | Leuprorelin Acetate Depot 3M, Leuprolide acetate Depot 3M | Takeda, Takeda | Central Precocious Puberty | 05/25 | 05/25 | | |
| Recruiting | 4 | 5 | RoW | Elaprase, Idursulfase | Takeda | Hunter Syndrome | 08/24 | 09/24 | | |
NCT05442554: A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma |
|
|
| Active, not recruiting | 4 | 10 | RoW | Brentuximab vedotin, SGN-35 | Takeda | T-Cell Lymphoma | 09/24 | 09/24 | | |
